On May 22, the Reagan-Udall Foundation for the FDA, in collaboration with the Food and Drug Administration, will host a virtual public workshop on "Primary Mitochondrial Diseases."
This workshop will explore opportunities to optimize therapeutic development addressing primary mitochondrial diseases and best practices in designing and interpreting clinical studies that can produce meaningful data to accelerate drug development for these rare diseases. Speakers will include patient advocates, academic researchers, regulated industry, healthcare providers, and other key stakeholders.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
